Tyra Biosciences Says Late-Breaking Abstract On TYRA-300 Preclinical Results Accepted For Presentation At ENDO 2025

Author: Benzinga Newsdesk | July 08, 2025 04:09pm

Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that a late-breaking abstract has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025), taking place July 12-15, 2025 in San Francisco, CA.

Details of the poster presentation are below:

• Title: "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia"
• Abstract: SUN-730
• Presenting Author: Jacqueline H. Starrett, Ph.D., Tyra Biosciences
• Date/Time: July 13, 2025, 12:00 PM - 1:30 PM, ENDOExpo: Poster Area
• Session: Session P70 - BONE AND MINERAL METABOLISM: Rare Bone and Genetic Disorders

Posted In: TYRA